Opinion

Luciano J Costa: S-MRD Negativity and Stopping Therapy Have Less Than 10% Risk of Progression or MRD Resurgence in 4 Years

Luciano Costa/LinkedIn

Jun 18, 2025, 10:35

Luciano J Costa: S-MRD Negativity and Stopping Therapy Have Less Than 10% Risk of Progression or MRD Resurgence in 4 Years

Luciano J Costa, Professor at University of Alabama at Birmingham, reshared his post on X, adding:

“Patients with standard risk Multiple Myeloma treated with QUADs + ASCT, achieving S-MRD negativity and stopping therapy have <10% risk of progression or MRD resurgence in 4 years!”

Quoting his original post:

“Optimal MRD-based end point to support response-adapted treatment cessation in NDMM.”

Title: Optimal MRD-based end point to support response-adapted treatment cessation in NDMM

Authors: Smith Giri, Binod Dhakal, Natalie S Callander, Eva Medvedova, Kelly Godby, Bhagirathbhai Dholaria, Susan Bal, Gayathri Ravi, Saurabh Chhabra, Rebecca Silbermann, Luciano J. Costa

Read Full Article.

Luciano J Costa

More posts featuring Luciano J Costa on OncoDaily.

Bhagirathbhai Dholaria Binod Dhakal cancer Eva Medvedova Gayathri Ravi Kelly Godby Luciano J Costa MRD-Guided Therapy multiple myeloma Natalie S Callander OncoDaily Oncology Rebecca Silbermann Saurabh Chhabra Smith Giri Susan Bal

Uhm Jung-hwa: Korea’s Iconic ‘Madonna’ and Her Triumphant Battle Against Thyroid Cancer

Vincent Rajkumar: A Historic Day for High Risk Smoldering Myeloma

Dr. Anastasia Constantinidou Nominated for Madame Figaro Woman of the Year 2025

Lisa A. Lacasse Welcomed Shane Jacobson as the New CEO of the ACS and the ACS CAN

ASCO and Community Oncology Alliance Have Released the Updated Oncology Medical Home Standards